Due to the increased safety precautions for our warehouse employees in relation to COVID-19, the order cutoff for same day shipping will be 5:00pm EST for Troy, MI warehouse and 5:00pm MTN for Salt Lake City, UT warehouse (4:00pm PST) until further notice.

Industry News

Auburn continually updates our product portfolio, ensuring that we are offering the most current generics that are available in the market. What’s more, our commitment to consumer and product safety is unparalleled - we notify customers of manufacturer recalls immediately and our protocols align with FDA regulations.


PRESIDENT’S UPDATE MARCH 2020

The FDA’s Office of Generic Drugs (OGD) recently released their 2019 Annual Report highlighting some of the accomplishments for the year.

With all of the talk of controlling rising drug costs, it would be a good idea for some of the politicians to get a better understanding of how generics pieces fit into the puzzle. In 2019 the FDA approved 1,014 final or tentative approvals. That’s almost four (4) approvals every business day of the year. Of these approvals, 110 of them were for complex drug applications and 107 were first time generic approvals.

Some of the big approvals to hit the market were generic Advair with generic sales estimated to reach over $650 million at a significant discount from the brand. Generic Delzicol hit the market in 2019 with sales estimated at over $100 million. Plus generic Lyrica was approved and launched by up to 10 manufacturers. Pfizer, who had reported past sales of close to $4 billion annually saw almost 90% of their market go to the generics. Prices fell from almost $7/does to approximately .10 cents.

So, hopefully the politicians understand that when they talk about drug costs increasing, and yes, sometimes even generics increase, overall generics continue to save consumers billions and billions of dollars each year. Don’t focus on the few that go up in price when market conditions change but rather look at the hundreds of generics that decrease on almost a daily basis.

The FDA has been in close contact with many generic companies to understand how the coronavirus (Covid-19) outbreak in China will impact the pharmaceutical market in the US this year. Based on some of their findings they are already reporting that they anticipate disruptions of finished goods coming from China as well as active and inactive ingredients of which China is a major supplier.

FDA has also announced that they have stopped pharmaceutical plant inspections in China and will rely on the company’s compliance history to determine whether drugs are safe for importing into the US. Given the compliance records of some, I find this a little frightening. We’ve been in touch with many of our suppliers on this issue and have been told that depending on the length of the outbreak they are expecting disruptions and possibly shortages over the next few months.

image of pills falling out of bottle

Generic Product Launch Dates

Below you will find a list of anticipated new generic launch dates* along with the estimated availability. If you are interested in learning more about which items Auburn Pharmaceutical may carry in the future, please contact us to open your account.

Brand Name Generic Name # of players Estimated Availability*
Zortress Everolims 3 potentially March 2020
Vimovo Esomeprazole/Maproxen 4 potentially 1st Quarter 2020
Sklice Ivermectin 1 Player May 2020
Saphris Asenapine Maleate 3 potentially 1st Half 2020
*This information is intended to provide you with the latest industry news around generic drug launch dates. Please note, there is no guarantee that Auburn Pharmaceutical will supply the listed products. Product release dates are subject to change by evolving market conditions. Launch dates are anticipated, not guaranteed.

Upcoming Events & Promotions

Stay tuned for upcoming events that Auburn Pharmaceutical will be attending.